Unlock stock picks and a broker-level newsfeed that powers Wall Street.

CLASS ACTION UPDATE for MO, CVET and OSTK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

In This Article:

NEW YORK, NY / ACCESSWIRE / October 3, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Altria Group, Inc. (MO)

Lawsuit on behalf of: investors who purchased December 20, 2018 - September 24, 2019
Lead Plaintiff Deadline : December 2, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/altria-group-inc-loss-form?prid=3795&wire=1

According to the filed complaint, during the class period, Altria Group, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Altria had conducted insufficient due diligence into JUUL prior to the Company's $12.8 billion investment, or 35% stake, in JUUL; (ii) Altria consequently failed to inform investors, or account for, material risks associated with JUUL's products and marketing practices, and the true value of JUUL and its products; (iii) all of the foregoing, as well as mounting public scrutiny, negative publicity, and governmental pressure on e-vapor products and JUUL made it reasonably likely that Altria's investment in JUUL would have a material negative impact on the Company's reputation and operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Covetrus, Inc. (CVET)

Lawsuit on behalf of: investors who purchased February 8, 2019 - August 12, 2019
Lead Plaintiff Deadline : November 29, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/covetrus-inc-loss-form?prid=3795&wire=1

According to the filed complaint, during the class period, Covetrus, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company had overstated its capabilities with regard to inventory management and supply chain services; (ii) Covetrus had understated the costs of the integration of Henry Schein's Animal Health Business and VFC, including the timing and nature of those costs; (iii) Covetrus had understated its separation costs from Henry Schein; and (iv) the Company understated the impact on earnings from online competition and alternative distribution channels as well as the impact of the loss of a large customer in North America just prior to the Company's separation from Henry Schein.